← All trials
NCT06907199
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2025
- Primary completion
- Jul 1, 2028
- Completion date
- Jan 30, 2029
- First posted
- Apr 2, 2025
- Last posted
- Nov 28, 2025
- Enrollment
- 104
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- The University of Texas, DallasLead sponsor
- University of Texas, GalvestonCollaborator
- The University of Texas, DallasSponsor investigator
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Collaborator
- National Institutes of Health (NIH)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.